Header Logo

Connection

Ajaypal Singh to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Ajaypal Singh has written about Treatment Outcome.
Ajaypal Singh
Connection Strength
1.002
Treatment Outcome
  1. Does Prescription Length of Buprenorphine Influence Treatment Outcomes in Opioid Use Disorder? A Retrospective Cohort Study from North India. Subst Use Misuse. 2023; 58(12):1620-1624.
    View in: PubMed
    Score: 0.124
  2. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
    View in: PubMed
    Score: 0.114
  3. Sudden cardiac arrest in ESRD patients. Clin Nephrol. 2014 Feb; 81(2):121-31.
    View in: PubMed
    Score: 0.064
  4. Message to the FDA on ESAs: REMS is not enough, more studies are needed. Clin J Am Soc Nephrol. 2010 Aug; 5(8):1355-8.
    View in: PubMed
    Score: 0.050
  5. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes. Heart Fail Clin. 2010 Jul; 6(3):323-32.
    View in: PubMed
    Score: 0.050
  6. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed? Am J Nephrol. 2010; 31(6):552-6; discussion 563-4.
    View in: PubMed
    Score: 0.050
  7. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.
    View in: PubMed
    Score: 0.049
  8. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010 Feb; 77(3):239-46.
    View in: PubMed
    Score: 0.048
  9. Interpreting results of clinical trials: a conceptual framework. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1246-52.
    View in: PubMed
    Score: 0.044
  10. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 Sep; 74(6):791-8.
    View in: PubMed
    Score: 0.044
  11. Is it time to reconsider subcutaneous administration of epoetin? Nephrol News Issues. 2007 Oct; 21(11):57, 59, 63-4 passim.
    View in: PubMed
    Score: 0.041
  12. The target hemoglobin in patients with chronic kidney disease. Nephrol News Issues. 2006 Dec; 20(13):29-30.
    View in: PubMed
    Score: 0.039
  13. Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database. Transplantation. 2006 Sep 15; 82(5):612-8.
    View in: PubMed
    Score: 0.038
  14. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease. Nephrol Nurs J. 2005 Mar-Apr; 32(2):199-206; quiz 207-8.
    View in: PubMed
    Score: 0.035
  15. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis. 2004 Dec; 44(6):1050-9.
    View in: PubMed
    Score: 0.034
  16. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 09; 17(9):1325-1336.
    View in: PubMed
    Score: 0.029
  17. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.
    View in: PubMed
    Score: 0.022
  18. The Prevalence, Clinical Spectrum and the Long Term Outcome of ST-segment Elevation Myocardial Infarction in Young - A Prospective Observational Study. Cardiovasc Revasc Med. 2019 05; 20(5):387-391.
    View in: PubMed
    Score: 0.022
  19. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Am J Nephrol. 2017; 46(5):364-370.
    View in: PubMed
    Score: 0.021
  20. Ferric pyrophosphate citrate (Triferic?) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 2015 Dec; 30(12):2019-26.
    View in: PubMed
    Score: 0.018
  21. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.
    View in: PubMed
    Score: 0.015
  22. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep; 60(3):390-401.
    View in: PubMed
    Score: 0.014
  23. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
    View in: PubMed
    Score: 0.014
  24. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
    View in: PubMed
    Score: 0.012
  25. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009 Jan; 53(1):26-32.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.